Venova Medical, a Los Gatos, CA-based company developing technology for the creation of percutaneous arteriovenous fistulas (pAVF) for hemodialysis access, raised $30M in Series B funding.
Catalyst Health Ventures and a medical device company co-led the financing, with participation from ShangBay Capital, Mirae Asset Capital, KOFA Healthcare, Cadence Healthcare Ventures, Aphelion Capital and other new and existing investors.
Related: Organ transplant tech pioneer lands £1.4m new funding
The company intends to use the funds to support clinical studies of the velocity pAVF system in patients with chronic and end-stage renal disease.
Co-founded by CEO Erik van der Burg, and Shant Vartanian, MD, Venova Medical is a addressing the challenges associated with providing optimal vascular access for patients needing hemodialysis. It has developed the velocity system, a percutaneous AVF technology designed to reduce the need for reinterventions to achieve fistula maturation and improve vascular access outcomes while reducing costs. The company is currently conducting the prospective, single center, single-arm VENOS-1 clinical trial (NCT05757726) which is evaluating the safety and feasibility of velocity system in patients on hemodialysis who are candidates for arteriovenous fistulas.
Venova Medical also announced the appointment of Darshana Zaveri, Managing Partner at Catalyst Health Ventures, to the company’s Board of Directors.
